Chimeric antigen receptor (CAR) T cells represent a major advance for immunotherapy. However, while CAR T cell approaches against liquid tumors have been successful, results against solid tumors are less promising. Moreover, costs and technical difficulties associated with phenotyping, profiling, and purifying immune cells further impede CAR T-cell therapeutics. In vitro assays such as flow cytometry and live-cell analysis are key to phenotyping and assessing immune cell function both prior to and following CAR introduction.
Download this white paper from Sartorius to learn more about how to phenotype and assess the function of CAR-modified immune cells, including T cells, NK cells, and macrophages.